ClinicalTrials.gg
CompletedNCT01392378Updated Feb 26, 2014Results posted

Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and INFANRIX hexa in Pneumococcal Vaccines, sponsored by Pfizer. Completed at 14 sites in Poland. Open to participants aged 56 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-26.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
908
Allocation
Randomized
Ages
56 Days to 98 Days
Sex
All
01

Study summary

The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.

02

Conditions studied

  • Pneumococcal Vaccines

Keywords

  • Prevenar 13
  • 13vPnC
  • Antipyretic medication
  • Healthy subjects
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
56 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2 months (56 to 98 days) at time of enrollment.
  • Healthy infant as determined by medical history, physical examination, and judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib conjugate vaccines.
  • A previous anaphylactic reaction to any vaccine or vaccine-related component.
  • Allergy or to paracetamol or ibuprofen administration.
  • Contraindication to vaccination with pneumococcal conjugate, diphtheria, tetanus, pertussis, polio, Hib, or vaccines.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
908 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Paracetamol

  • Experimental
    Group 2

    Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Ibuprofen

  • Experimental
    Group 3

    Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Paracetamol

  • Experimental
    Group 4

    Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Ibuprofen

  • Experimental
    Group 5

    Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa

Interventions

  • 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • BiologicalINFANRIX hexa

    INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

  • 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • BiologicalINFANRIX hexa

    INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

  • 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • BiologicalINFANRIX hexa

    INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

  • 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • BiologicalINFANRIX hexa

    INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

  • 13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

  • BiologicalINFANRIX hexa

    INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series

    Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 month after the infant series

Secondary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the infant series

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose

    Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively.

    Time frame: 1 month after the toddler dose

  3. Percentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series

    Percentage of participants achieving serotype-specific pneumococcal OPA titer \>= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13.

    Time frame: 1 month after the infant series

  4. Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series

    Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: 1 month after the infant series

  5. Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series

    Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.

    Time frame: 1 month after the infant series

  6. Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series

    Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.

    Time frame: 1 month after the infant series

  7. Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series

    Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.

    Time frame: 1 month after the infant series

  8. Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series

    Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.

    Time frame: 1 month after the infant series

  9. Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series

    Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.

    Time frame: 1 month after the infant series

  10. Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose

    Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.

    Time frame: 1 month after the toddler dose

  11. Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose

    Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.

    Time frame: 1 month after the toddler dose

  12. Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose

    Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.

    Time frame: 1 month after the toddler dose

  13. Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose

    Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.

    Time frame: 1 month after the toddler dose

  14. Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose

    Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.

    Time frame: 1 month after the toddler dose

  15. Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series

    Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.6 EU/mL, FHA \>=16.1 EU/mL, PRN \>=24.0 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.

    Time frame: 1 month after the infant series

  16. Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose

    Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.8 EU/mL, FHA \>=46.5 EU/mL, PRN \>=43.5 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.

    Time frame: 1 month after the toddler dose

  17. Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1

    Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree Celsius (degree C), greater than (\>) 39 but \<=40 degree C and \>40 degree C.

    Time frame: Within 4 days after infant series Dose 1

  18. Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2

    Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.

    Time frame: Within 4 days after infant series Dose 2

  19. Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3

    Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C. Report of fever \>40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error.

    Time frame: Within 4 days after infant series Dose 3

  20. Percentage of Participants Reporting Fever Within 4 Days: Toddler Dose

    Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.

    Time frame: Within 4 days after toddler dose

  21. Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).

    Time frame: Baseline up to 1 Month (28 to 42 days) after infant series

  22. Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment).

    Time frame: 1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose

  23. Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).

    Time frame: Toddler dose up to 1 Month (28 to 42 days) after toddler dose

07

Results

Posted Feb 26, 2014

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Started173176172177210
Vaccinated dose 1173176172177210
Vaccinated dose 2171174172177210
Vaccinated dose 3170174172176210
Completed169174172175210
Not completed42020
Withdrew: Adverse event00010
Withdrew: Lost to follow-up00010
Withdrew: Protocol violation01000
Withdrew: Withdrawal by parent41000
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Started169174172175210
Completed169173170175209
Not completed01201
Withdrew: Lost to follow-up00100
Withdrew: Withdrawal by parent01101
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Started169173170175209
Completed169172170173208
Not completed01021
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by parent01011

Outcome measures

PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series

Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series
microgram per milliliter (mcg/mL)13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
4 (n = 137, 155, 148, 146, 210)1.64 (1.44 to 1.87)1.99 (1.76 to 2.25)1.48 (1.31 to 1.68)2.07 (1.82 to 2.34)2.02 (1.82 to 2.25)
6B (n = 136, 155, 148, 146, 210)0.68 (0.55 to 0.83)0.91 (0.76 to 1.10)0.56 (0.46 to 0.68)0.90 (0.74 to 1.09)0.81 (0.69 to 0.96)
9V (n = 138, 155, 148, 147, 210)1.13 (1.01 to 1.27)1.45 (1.30 to 1.61)1.17 (1.05 to 1.30)1.40 (1.26 to 1.56)1.31 (1.19 to 1.43)
14 (n = 138, 155, 148, 147, 210)4.45 (3.76 to 5.26)4.73 (4.04 to 5.54)4.75 (4.04 to 5.58)5.26 (4.48 to 6.19)5.38 (4.70 to 6.16)
18C (n = 138, 155, 148, 147, 210)1.47 (1.29 to 1.66)1.73 (1.54 to 1.95)1.25 (1.11 to 1.42)1.75 (1.55 to 1.97)1.54 (1.39 to 1.70)
19F (n = 138, 155, 148, 147, 210)1.78 (1.57 to 2.02)2.30 (2.04 to 2.59)1.59 (1.41 to 1.80)2.04 (1.81 to 2.31)1.99 (1.80 to 2.20)
23F (n= 137, 155, 148, 146, 210)0.85 (0.72 to 1.00)1.19 (1.02 to 1.40)0.73 (0.62 to 0.86)1.07 (0.91 to 1.26)1.04 (0.91 to 1.19)
1 (n = 138, 155, 148, 147, 210)1.12 (0.98 to 1.27)1.50 (1.33 to 1.69)1.02 (0.90 to 1.16)1.29 (1.14 to 1.47)1.25 (1.12 to 1.38)
3 (n = 138, 155, 148, 147, 210)0.71 (0.63 to 0.79)0.83 (0.75 to 0.93)0.57 (0.51 to 0.64)0.84 (0.75 to 0.94)0.88 (0.79 to 0.96)
5 (n = 137, 155, 148, 146, 210)0.79 (0.69 to 0.91)0.98 (0.86 to 1.11)0.63 (0.55 to 0.72)0.90 (0.78 to 1.02)0.81 (0.73 to 0.91)
6A (n = 138, 155, 148, 146, 210)0.97 (0.84 to 1.13)1.25 (1.09 to 1.44)0.85 (0.74 to 0.98)1.22 (1.06 to 1.41)1.10 (0.97 to 1.24)
7F (n = 138, 155, 148, 146, 210)1.94 (1.74 to 2.16)2.22 (2.01 to 2.46)1.83 (1.65 to 2.03)2.28 (2.06 to 2.53)2.15 (1.97 to 2.34)
19A (n = 137, 155, 148, 146, 210)2.70 (2.38 to 3.07)3.39 (3.01 to 3.82)2.53 (2.24 to 2.86)3.14 (2.77 to 3.55)3.02 (2.72 to 3.34)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0856 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.81 · 95% CI 0.69 to 0.96
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8546 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.84 to 1.16
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0012 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.73 · 95% CI 0.62 to 0.86
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.02 · 95% CI 0.87 to 1.20
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.83 · 95% CI 0.64 to 1.08
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.4548 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.13 · 95% CI 0.88 to 1.44
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0093 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.69 · 95% CI 0.53 to 0.88
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.10 · 95% CI 0.86 to 1.42
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.1749 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.87 · 95% CI 0.75 to 1.00
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.11 · 95% CI 0.96 to 1.27
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.1351 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.89 · 95% CI 0.78 to 1.03
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.07 · 95% CI 0.93 to 1.24
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2158 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.83 · 95% CI 0.67 to 1.03
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3279 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.88 · 95% CI 0.71 to 1.08
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2472 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.88 · 95% CI 0.72 to 1.09
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.79 to 1.21
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6193 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.81 to 1.12
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.13 · 95% CI 0.96 to 1.32
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0191 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.82 · 95% CI 0.70 to 0.96
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.14 · 95% CI 0.97 to 1.33
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.76 to 1.05
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.15 · 95% CI 0.99 to 1.35
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0135 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.80 · 95% CI 0.68 to 0.94
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.87 to 1.21
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.1749 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.81 · 95% CI 0.66 to 1.00
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.15 · 95% CI 0.93 to 1.41
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0038 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.70 · 95% CI 0.57 to 0.86
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.84 to 1.27
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.76 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2053 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.20 · 95% CI 1.02 to 1.41
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0241 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.82 · 95% CI 0.70 to 0.96
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.88 to 1.22
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0732 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.81 · 95% CI 0.69 to 0.94
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6090 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.82 to 1.10
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = <0.0001 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.65 · 95% CI 0.56 to 0.76
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.96 · 95% CI 0.82 to 1.11
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7828 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.82 to 1.16
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2053 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.21 · 95% CI 1.02 to 1.43
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0093 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.77 · 95% CI 0.65 to 0.92
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.11 · 95% CI 0.93 to 1.31
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.88 · 95% CI 0.73 to 1.07
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.14 · 95% CI 0.95 to 1.37
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0135 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.77 · 95% CI 0.64 to 0.93
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.11 · 95% CI 0.92 to 1.34
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.79 to 1.03
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6652 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.91 to 1.18
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0275 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.75 to 0.98
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.06 · 95% CI 0.93 to 1.21
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2412 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.76 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3121 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.13 · 95% CI 0.96 to 1.32
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0387 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.84 · 95% CI 0.72 to 0.99
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8414 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.89 to 1.22
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
4 (n = 137, 155, 148, 146, 210)96.4 (91.69 to 98.80)97.4 (93.52 to 99.29)96.6 (92.29 to 98.89)97.3 (93.13 to 99.25)98.1 (95.20 to 99.48)
6B (n = 136, 155, 148, 146, 210)72.8 (64.50 to 80.07)80.0 (72.83 to 85.99)61.5 (53.14 to 69.36)79.5 (71.98 to 85.69)77.6 (71.37 to 83.07)
9V (n = 138, 155, 148, 147, 210)94.2 (88.90 to 97.46)99.4 (96.46 to 99.98)95.9 (91.39 to 98.50)95.9 (91.33 to 98.49)96.2 (92.63 to 98.34)
14 (n = 138, 155, 148, 147, 210)100.0 (97.36 to 100.00)98.7 (95.42 to 99.84)99.3 (96.29 to 99.98)98.6 (95.17 to 99.83)99.5 (97.38 to 99.99)
18C (n = 138, 155, 148, 147, 210)96.4 (91.75 to 98.81)97.4 (93.52 to 99.29)95.3 (90.50 to 98.08)95.9 (91.33 to 98.49)96.7 (93.25 to 98.65)
19F (n = 138, 155, 148, 147, 210)97.1 (92.74 to 99.20)99.4 (96.46 to 99.98)95.3 (90.50 to 98.08)96.6 (92.24 to 98.89)97.6 (94.53 to 99.22)
23F (n = 137, 155, 148, 146, 210)86.1 (79.19 to 91.44)90.3 (84.54 to 94.48)74.3 (66.50 to 81.15)88.4 (82.01 to 93.07)88.1 (82.93 to 92.15)
1 (n = 138, 155, 148, 147, 210)94.2 (88.90 to 97.46)97.4 (93.52 to 99.29)90.5 (84.64 to 94.73)94.6 (89.56 to 97.62)94.3 (90.23 to 97.01)
3 (n = 138, 155, 148, 147, 210)83.3 (76.05 to 89.13)89.7 (83.78 to 93.98)81.1 (73.83 to 87.05)88.4 (82.13 to 93.12)91.0 (86.23 to 94.46)
5 (n = 137, 155, 148, 146, 210)84.7 (77.53 to 90.25)91.0 (85.31 to 94.97)76.4 (68.68 to 82.94)89.7 (83.62 to 94.13)84.3 (78.65 to 88.93)
6A (n = 138, 155, 148, 146, 210)86.2 (79.34 to 91.50)92.3 (86.87 to 95.94)83.1 (76.08 to 88.76)91.8 (86.08 to 95.68)91.9 (87.36 to 95.21)
7F (n = 138, 155, 148, 146, 210)100.0 (97.36 to 100.00)99.4 (96.46 to 99.98)97.3 (93.22 to 99.26)100.0 (97.51 to 100.00)99.5 (97.38 to 99.99)
19A (n = 137, 155, 148, 146, 210)98.5 (94.83 to 99.82)99.4 (96.46 to 99.98)98.0 (94.19 to 99.58)99.3 (96.24 to 99.98)100.0 (98.26 to 100.00)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose

Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose
mcg/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
4 (n = 130, 144, 143, 139, 206)3.07 (2.66 to 3.54)3.43 (3.00 to 3.93)2.97 (2.60 to 3.41)3.43 (2.99 to 3.94)3.10 (2.77 to 3.48)
6B (n = 130, 144, 143, 139, 206)6.70 (5.76 to 7.78)8.01 (6.94 to 9.24)6.38 (5.53 to 7.36)7.30 (6.31 to 8.44)7.08 (6.28 to 7.98)
9V (n = 130, 144, 143, 139, 206)2.15 (1.93 to 2.40)2.23 (2.01 to 2.47)2.17 (1.96 to 2.41)2.12 (1.91 to 2.35)2.16 (1.99 to 2.36)
14 (n = 130, 144, 143, 139, 206)8.10 (7.04 to 9.31)8.40 (7.36 to 9.59)7.95 (6.96 to 9.08)9.12 (7.96 to 10.43)9.10 (8.15 to 10.17)
18C (n = 130, 144, 143, 139, 206)1.35 (1.20 to 1.53)1.68 (1.49 to 1.88)1.36 (1.21 to 1.53)1.63 (1.45 to 1.84)1.59 (1.44 to 1.75)
19F (n = 130, 144, 143, 139, 206)8.41 (7.17 to 9.87)8.99 (7.72 to 10.46)7.53 (6.47 to 8.76)8.02 (6.88 to 9.36)7.95 (7.00 to 9.02)
23F (n = 130, 144, 142, 139, 206)2.34 (2.01 to 2.73)2.96 (2.56 to 3.43)2.37 (2.05 to 2.75)2.86 (2.47 to 3.32)2.75 (2.43 to 3.10)
1 (n = 130, 144, 143, 139, 206)2.80 (2.47 to 3.17)3.22 (2.85 to 3.62)2.66 (2.36 to 3.00)3.12 (2.76 to 3.52)3.04 (2.75 to 3.35)
3 (n = 129, 144, 143, 138, 203)0.46 (0.40 to 0.52)0.54 (0.47 to 0.61)0.46 (0.40 to 0.52)0.49 (0.42 to 0.55)0.54 (0.48 to 0.60)
5 (n = 130, 144, 143, 139, 206)2.33 (2.07 to 2.63)2.75 (2.46 to 3.07)2.40 (2.15 to 2.69)2.62 (2.33 to 2.93)2.84 (2.59 to 3.12)
6A (n = 130, 144, 143, 139, 206)5.12 (4.48 to 5.86)5.73 (5.04 to 6.50)5.27 (4.64 to 5.99)5.36 (4.70 to 6.10)5.52 (4.97 to 6.14)
7F (n = 130, 144, 142, 139, 206)3.79 (3.42 to 4.19)3.89 (3.54 to 4.28)3.56 (3.23 to 3.92)3.97 (3.60 to 4.38)3.98 (3.67 to 4.31)
19A (n = 129, 144, 142, 139, 206)7.11 (6.22 to 8.12)7.99 (7.04 to 9.06)7.31 (6.43 to 8.30)7.35 (6.47 to 8.36)7.71 (6.94 to 8.57)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9350 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.82 to 1.19
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.11 · 95% CI 0.93 to 1.32
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6922 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.96 · 95% CI 0.80 to 1.14
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.11 · 95% CI 0.93 to 1.32
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6915 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.78 to 1.15
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.13 · 95% CI 0.94 to 1.36
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.4389 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.75 to 1.09
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.85 to 1.24
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9350 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.87 to 1.14
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.90 to 1.18
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9430 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.00 · 95% CI 0.88 to 1.15
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.85 to 1.12
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5167 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.89 · 95% CI 0.74 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.78 to 1.10
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.87 · 95% CI 0.73 to 1.04
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9872 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.00 · 95% CI 0.84 to 1.19
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2582 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.73 to 1.00
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.06 · 95% CI 0.91 to 1.23
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.74 to 1.00
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.88 to 1.20
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6915 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.06 · 95% CI 0.86 to 1.30
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.13 · 95% CI 0.93 to 1.38
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6922 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.78 to 1.15
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9872 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.01 · 95% CI 0.83 to 1.23
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3609 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.70 to 1.04
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.08 · 95% CI 0.89 to 1.30
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.71 to 1.05
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.86 to 1.26
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6304 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.79 to 1.08
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.06 · 95% CI 0.91 to 1.24
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.88 · 95% CI 0.75 to 1.03
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.88 to 1.20
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2582 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.84 · 95% CI 0.71 to 1.01
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9279 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.84 to 1.18
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.72 to 1.01
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.76 to 1.07
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.1424 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.82 · 95% CI 0.71 to 0.96
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.97 · 95% CI 0.84 to 1.12
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.73 to 0.98
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.79 to 1.07
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6304 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.93 · 95% CI 0.78 to 1.10
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.88 to 1.22
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6922 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.81 to 1.13
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.97 · 95% CI 0.82 to 1.15
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6572 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.84 to 1.08
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.86 to 1.11
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2514 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.89 · 95% CI 0.79 to 1.01
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9872 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.00 · 95% CI 0.88 to 1.13
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6304 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.78 to 1.09
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7918 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.88 to 1.22
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.6922 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.80 to 1.12
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9765 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.81 to 1.13
SecondaryPercentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series

Percentage of participants achieving serotype-specific pneumococcal OPA titer \>= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
4 (n = 37, 46, 42, 41, 61)100.0 (90.5 to 100.0)100.0 (92.3 to 100.0)100.0 (91.6 to 100.0)100.0 (91.4 to 100.0)100.0 (94.1 to 100.0)
6B (n = 36, 45, 43, 40, 62)94.4 (81.3 to 99.3)88.9 (75.9 to 96.3)88.4 (74.9 to 96.1)92.5 (79.6 to 98.4)96.8 (88.8 to 99.6)
9V (n = 37, 48, 42, 41, 65)62.2 (44.8 to 77.5)66.7 (51.6 to 79.6)59.5 (43.3 to 74.4)80.5 (65.1 to 91.2)75.4 (63.1 to 85.2)
14 (n = 38, 48, 41, 41, 64)89.5 (75.2 to 97.1)97.9 (88.9 to 99.9)100.0 (91.4 to 100.0)97.6 (87.1 to 99.9)96.9 (89.2 to 99.6)
18C (n = 37, 47, 41, 41, 62)100.0 (90.5 to 100.0)95.7 (85.5 to 99.5)100.0 (91.4 to 100.0)97.6 (87.1 to 99.9)100.0 (94.2 to 100.0)
19F (n = 37, 46, 41, 42, 63)97.3 (85.8 to 99.9)87.0 (73.7 to 95.1)90.2 (76.9 to 97.3)92.9 (80.5 to 98.5)95.2 (86.7 to 99.0)
23F (n = 38, 45, 42, 42, 63)92.1 (78.6 to 98.3)97.8 (88.2 to 99.9)92.9 (80.5 to 98.5)90.5 (77.4 to 97.3)93.7 (84.5 to 98.2)
1 (n = 42, 42, 43, 44, 74)47.6 (32.0 to 63.6)42.9 (27.7 to 59.0)30.2 (17.2 to 46.1)29.5 (16.8 to 45.2)45.9 (34.3 to 57.9)
3 (n = 41, 41, 39, 39, 69)97.6 (87.1 to 99.9)97.6 (87.1 to 99.9)97.4 (86.5 to 99.9)94.9 (82.7 to 99.4)100.0 (94.8 to 100.0)
5 (n = 42, 43, 44, 42, 73)92.9 (80.5 to 98.5)90.7 (77.9 to 97.4)86.4 (72.6 to 94.8)92.9 (80.5 to 98.5)86.3 (76.2 to 93.2)
6A (n = 46, 42, 39, 39, 76)93.5 (82.1 to 98.6)100.0 (91.6 to 100.0)100.0 (91.0 to 100.0)100.0 (91.0 to 100.0)98.7 (92.9 to 100.0)
7F (n = 46, 42, 40, 39, 76)100.0 (92.3 to 100.0)100.0 (91.6 to 100.0)100.0 (91.2 to 100.0)97.4 (86.5 to 99.9)100.0 (95.3 to 100.0)
19A (n = 42, 44, 41, 42, 74)92.9 (80.5 to 98.5)100.0 (92.0 to 100.0)90.2 (76.9 to 97.3)88.1 (74.4 to 96.0)97.3 (90.6 to 99.7)
SecondaryGeometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series

Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
1 month after the infant series
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series
titer13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
4 (n = 37, 46, 42, 41, 61)1269 (961.2 to 1674.2)1135 (885.2 to 1456.1)1240 (955.9 to 1609.3)1361 (1045.4 to 1771.0)1086 (874.9 to 1347.9)
6B (n = 36, 45, 43, 40, 62)794 (450.4 to 1399.6)655 (394.6 to 1087.9)470 (279.9 to 789.7)663 (387.2 to 1135.1)748 (485.6 to 1152.0)
9V (n = 37, 48, 42, 41, 65)120 (52.5 to 274.2)166 (80.5 to 343.3)93 (43.0 to 203.0)285 (129.8 to 623.8)241 (129.0 to 448.7)
14 (n = 38, 48, 41, 41, 64)435 (277.2 to 683.5)622 (416.0 to 928.6)650 (420.7 to 1003.0)991 (642.1 to 1530.9)951 (671.6 to 1346.3)
18C (n = 37, 47, 41, 41, 62)1094 (777.8 to 1539.2)853 (630.0 to 1154.3)877 (634.1 to 1212.7)1031 (745.8 to 1426.2)1092 (838.9 to 1421.3)
19F (n = 37, 46, 41, 42, 63)346 (219.7 to 545.4)221 (146.8 to 331.9)165 (106.8 to 253.4)294 (191.8 to 450.2)279 (196.8 to 395.0)
23F (n = 38, 45, 42, 42, 63)342 (211.6 to 552.6)441 (283.7 to 685.4)332 (210.0 to 523.4)321 (203.3 to 506.7)366 (252.4 to 532.1)
1 (n = 42, 42, 43, 44, 74)12 (8.7 to 17.7)11 (7.5 to 15.4)8 (5.5 to 11.2)8 (5.4 to 10.9)12 (9.0 to 15.5)
3 (n = 41, 41, 39, 39, 69)72 (57.4 to 91.1)76 (60.4 to 95.7)56 (44.1 to 70.8)62 (49.3 to 79.1)87 (73.1 to 104.3)
5 (n = 42, 43, 44, 42, 73)86 (59.7 to 122.7)96 (67.4 to 137.3)54 (37.7 to 76.2)99 (69.1 to 142.0)76 (57.5 to 99.2)
6A (n = 46, 42, 39, 39, 76)1060 (784.5 to 1431.1)1681 (1227.3 to 2302.3)1228 (886.0 to 1701.9)1281 (924.0 to 1775.1)1462 (1157.1 to 1847.1)
7F (n = 46, 42, 40, 39, 76)1766 (1387.0 to 2247.7)1907 (1481.0 to 2454.6)1747 (1348.6 to 2263.3)1584 (1218.8 to 2058.9)2125 (1761.6 to 2564.6)
19A (n = 42, 44, 41, 42, 74)185 (127.8 to 268.3)257 (178.5 to 368.5)163 (112.3 to 237.9)159 (110.0 to 230.9)240 (181.9 to 318.0)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7148 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.2 · 95% CI 0.82 to 1.66
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7907 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.0 · 95% CI 0.75 to 1.45
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.4765 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.81 to 1.60
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5037 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.3 · 95% CI 0.89 to 1.76
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9414 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.52 to 2.17
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7907 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.45 to 1.71
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2900 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.6 · 95% CI 0.32 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.44 to 1.77
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5823 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.5 · 95% CI 0.18 to 1.40
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.27 to 1.80
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2407 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.4 · 95% CI 0.14 to 1.05
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.2 · 95% CI 0.43 to 3.22
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0961 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.5 · 95% CI 0.26 to 0.81
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.38 to 1.11
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2900 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.39 to 1.19
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.0 · 95% CI 0.60 to 1.82
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9925 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.0 · 95% CI 0.65 to 1.54
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.52 to 1.17
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3929 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.53 to 1.22
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.62 to 1.43
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7433 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.2 · 95% CI 0.70 to 2.20
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.46 to 1.35
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2407 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.6 · 95% CI 0.34 to 1.03
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.61 to 1.83
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9414 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.51 to 1.71
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.2 · 95% CI 0.68 to 2.14
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7380 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.50 to 1.63
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.49 to 1.58
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.9414 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.67 to 1.65
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7907 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.58 to 1.43
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2407 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.43 to 1.04
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2670 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.42 to 1.02
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5823 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.62 to 1.11
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.65 to 1.16
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.0422 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.6 · 95% CI 0.48 to 0.86
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2670 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.53 to 0.96
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8454 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.72 to 1.78
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.3 · 95% CI 0.81 to 2.00
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2824 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.45 to 1.11
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5155 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.3 · 95% CI 0.83 to 2.06
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5823 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.50 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.78 to 1.70
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.4644 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.56 to 1.25
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.8826 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.59 to 1.31
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5823 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.61 to 1.13
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7636 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.9 · 95% CI 0.65 to 1.23
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.3299 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.60 to 1.13
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2670 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.54 to 1.03
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.5823 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.8 · 95% CI 0.48 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.7907 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.1 · 95% CI 0.68 to 1.69
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2742 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.43 to 1.09
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.2670 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.7 · 95% CI 0.42 to 1.05
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series

Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series
mcg/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series0.54 (0.44 to 0.66)0.59 (0.49 to 0.73)0.49 (0.40 to 0.60)0.51 (0.42 to 0.63)0.58 (0.49 to 0.69)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.813 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.93 · 95% CI 0.71 to 1.22
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.845 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.79 to 1.34
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.461 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.65 to 1.11
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.545 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.89 · 95% CI 0.68 to 1.16
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series
EU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Pertussis PT40.86 (36.49 to 45.76)43.51 (39.02 to 48.51)40.27 (36.09 to 44.93)39.26 (35.04 to 43.98)44.85 (40.84 to 49.25)
Pertussis FHA46.29 (41.49 to 51.65)40.65 (36.59 to 45.16)41.32 (37.16 to 45.94)35.55 (31.85 to 39.68)48.42 (44.22 to 53.01)
Pertussis PRN72.90 (63.26 to 84.01)71.26 (62.18 to 81.66)65.82 (57.38 to 75.50)68.53 (59.44 to 79.02)84.57 (75.21 to 95.09)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.712 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.91 · 95% CI 0.79 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.837 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.97 · 95% CI 0.84 to 1.12
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.357 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.78 to 1.04
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.190 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.88 · 95% CI 0.76 to 1.01
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.813 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.96 · 95% CI 0.83 to 1.10
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.136 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.84 · 95% CI 0.73 to 0.96
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.104 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.85 · 95% CI 0.74 to 0.98
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = <0.001 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.73 · 95% CI 0.64 to 0.85
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.712 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.72 to 1.04
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.206 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.84 · 95% CI 0.70 to 1.01
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.066 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.78 · 95% CI 0.65 to 0.93
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.085 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.81 · 95% CI 0.67 to 0.97
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series
IU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Tetanus0.73 (0.65 to 0.83)0.70 (0.62 to 0.79)0.69 (0.61 to 0.77)0.60 (0.53 to 0.68)0.82 (0.74 to 0.90)
Diphtheria0.62 (0.56 to 0.69)0.68 (0.61 to 0.75)0.61 (0.55 to 0.68)0.65 (0.59 to 0.73)0.65 (0.60 to 0.72)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.712 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.90 · 95% CI 0.77 to 1.06
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.206 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.74 to 1.00
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.104 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.84 · 95% CI 0.72 to 0.98
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.001 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.74 · 95% CI 0.63 to 0.87
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.813 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.95 · 95% CI 0.82 to 1.09
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.837 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.90 to 1.19
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.534 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.93 · 95% CI 0.81 to 1.07
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.961 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.00 · 95% CI 0.87 to 1.15
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series

Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · mIU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series
mIU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series756.42 (589.71 to 970.26)770.93 (608.34 to 976.98)689.34 (546.12 to 870.11)599.12 (470.78 to 762.43)733.29 (597.81 to 899.46)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.03 · 95% CI 0.75 to 1.42
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.837 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.05 · 95% CI 0.77 to 1.44
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.695 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.94 · 95% CI 0.69 to 1.28
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.408 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.82 · 95% CI 0.60 to 1.12
SecondaryGeometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series

Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series
titer13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Poliomyelitis Type 168.11 (53.14 to 87.30)66.59 (52.98 to 83.68)67.43 (52.89 to 85.96)70.66 (54.73 to 91.23)72.02 (58.88 to 88.10)
Poliomyelitis Type 279.60 (61.54 to 102.95)73.52 (58.01 to 93.16)62.12 (48.30 to 79.90)55.17 (42.33 to 71.89)67.37 (54.67 to 83.02)
Poliomyelitis Type 3246.22 (192.84 to 314.38)184.03 (146.96 to 230.46)257.92 (203.08 to 327.56)218.85 (170.18 to 281.44)231.02 (189.44 to 281.72)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.813 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.95 · 95% CI 0.69 to 1.30
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.837 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.92 · 95% CI 0.68 to 1.25
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.695 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.94 · 95% CI 0.68 to 1.28
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.961 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.98 · 95% CI 0.71 to 1.36
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.808 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.18 · 95% CI 0.85 to 1.65
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.837 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.09 · 95% CI 0.80 to 1.50
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.695 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.92 · 95% CI 0.66 to 1.28
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.408 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.82 · 95% CI 0.58 to 1.15
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.813 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.07 · 95% CI 0.78 to 1.46
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.343 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.80 · 95% CI 0.59 to 1.08
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.695 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.12 · 95% CI 0.82 to 1.52
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.925 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.95 · 95% CI 0.69 to 1.31
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose
mcg/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose9.65 (7.74 to 12.03)9.35 (7.55 to 11.57)8.25 (6.69 to 10.16)7.84 (6.35 to 9.68)8.96 (7.53 to 10.67)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.08 · 95% CI 0.81 to 1.43
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.79 to 1.37
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.70 to 1.21
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.914 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.87 · 95% CI 0.67 to 1.15
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose
EU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Pertussis PT77.43 (68.12 to 88.02)76.93 (68.13 to 86.87)73.72 (65.40 to 83.10)73.38 (64.96 to 82.90)74.01 (66.91 to 81.86)
Pertussis FHA115.55 (104.32 to 128.00)117.87 (106.98 to 129.87)123.56 (112.30 to 135.95)108.11 (98.09 to 119.16)117.01 (107.97 to 126.81)
Pertussis PRN158.28 (136.30 to 183.81)156.98 (136.24 to 180.87)160.96 (139.98 to 185.08)158.71 (137.67 to 182.97)172.80 (153.64 to 194.36)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.05 · 95% CI 0.89 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.04 · 95% CI 0.89 to 1.22
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.961 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.00 · 95% CI 0.85 to 1.16
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.85 to 1.16
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.99 · 95% CI 0.87 to 1.12
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.909 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.01 · 95% CI 0.89 to 1.14
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.06 · 95% CI 0.93 to 1.20
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.914 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.81 to 1.05
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.76 to 1.11
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.91 · 95% CI 0.76 to 1.09
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.93 · 95% CI 0.78 to 1.12
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.914 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.92 · 95% CI 0.76 to 1.10
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose
IU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Tetanus2.54 (2.28 to 2.83)2.50 (2.26 to 2.77)2.60 (2.35 to 2.88)2.29 (2.07 to 2.54)2.66 (2.44 to 2.89)
Diphtheria1.64 (1.49 to 1.80)1.94 (1.77 to 2.12)1.69 (1.54 to 1.84)1.87 (1.71 to 2.04)1.90 (1.77 to 2.05)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.96 · 95% CI 0.83 to 1.10
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.94 · 95% CI 0.82 to 1.07
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.939 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.86 to 1.12
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.279 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.75 to 0.98
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.149 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.86 · 95% CI 0.76 to 0.97
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.02 · 95% CI 0.91 to 1.14
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.394 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.89 · 95% CI 0.79 to 0.99
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 0.98 · 95% CI 0.87 to 1.10
SecondaryGeometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · mIU/mL
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose
mIU/mL13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose4868.61 (3750.57 to 6319.94)4148.04 (3234.82 to 5319.08)4250.41 (3320.88 to 5440.13)4263.28 (3330.93 to 5456.60)3866.37 (3146.78 to 4750.52)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.869 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.26 · 95% CI 0.90 to 1.76
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.07 · 95% CI 0.78 to 1.48
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.10 · 95% CI 0.80 to 1.52
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmc ratio: 1.10 · 95% CI 0.80 to 1.52
SecondaryGeometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose

Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.

Time frame:
1 month after the toddler dose
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose
titer13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Poliomyelitis Type 1399.56 (332.13 to 480.68)426.63 (357.15 to 509.62)443.97 (373.58 to 527.63)415.45 (348.48 to 495.29)406.37 (351.67 to 469.59)
Poliomyelitis Type 2613.18 (515.30 to 729.65)586.30 (496.01 to 693.03)587.56 (499.47 to 691.18)605.78 (513.44 to 714.73)621.07 (542.07 to 711.57)
Poliomyelitis Type 31205.80 (1001.18 to 1452.24)1045.57 (874.35 to 1250.32)1210.29 (1017.32 to 1439.87)1187.11 (994.68 to 1416.76)1237.86 (1070.27 to 1431.70)
Statistical analysis
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.98 · 95% CI 0.78 to 1.24
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.05 · 95% CI 0.83 to 1.32
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.09 · 95% CI 0.87 to 1.37
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 1.02 · 95% CI 0.81 to 1.28
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.99 · 95% CI 0.79 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.94 · 95% CI 0.76 to 1.17
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.868 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.95 · 95% CI 0.77 to 1.17
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.98 · 95% CI 0.79 to 1.21
  • 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.910 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.97 · 95% CI 0.77 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.850 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.84 · 95% CI 0.67 to 1.06
  • 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.939 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.98 · 95% CI 0.78 to 1.23
  • 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily vs 13vPnC + INFANRIX Hexa · General Linear Model · p = 0.916 (P-values were adjusted using false discovery rate procedure.) · Gmt ratio: 0.96 · 95% CI 0.76 to 1.21
SecondaryPercentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series

Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.6 EU/mL, FHA \>=16.1 EU/mL, PRN \>=24.0 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Hib PRP >=0.15 mcg/mL (n= 136, 146, 144, 139, 198)87.5 (80.7 to 92.5)84.2 (77.3 to 89.7)86.1 (79.4 to 91.3)85.6 (78.7 to 91.0)87.9 (82.5 to 92.1)
Hib PRP >=1 mcg/mL (n = 136, 146, 144, 139, 198)33.8 (25.9 to 42.4)37.0 (29.2 to 45.4)27.1 (20.0 to 35.1)28.1 (20.8 to 36.3)33.8 (27.3 to 40.9)
Pertussis PT >=14.6 EU/mL (n= 132,143,141,131,193)93.2 (87.5 to 96.8)97.2 (93.0 to 99.2)91.5 (85.6 to 95.5)90.8 (84.5 to 95.2)95.3 (91.3 to 97.8)
Pertussis FHA >=16.1 EU/mL (n=132,143,141,131,193)96.2 (91.4 to 98.8)92.3 (86.7 to 96.1)93.6 (88.2 to 97.0)88.5 (81.8 to 93.4)95.3 (91.3 to 97.8)
Pertussis PRN >=24.0 EU/mL (n=132,143,141,131,193)90.9 (84.7 to 95.2)87.4 (80.8 to 92.4)88.7 (82.2 to 93.4)89.3 (82.7 to 94.0)95.3 (91.3 to 97.8)
Tetanus >=0.1 IU/mL (n = 132,143,141,131,193)100.0 (97.2 to 100.00)100.0 (97.5 to 100.00)100.0 (97.4 to 100.00)98.5 (94.6 to 99.8)99.5 (97.1 to 100.0)
Diphtheria >=0.1 IU/mL (n = 132,143,141,131,193)100.0 (97.2 to 100.00)98.6 (95.0 to 99.8)99.3 (96.1 to 100.0)97.7 (93.5 to 99.5)99.5 (97.1 to 100.0)
HBV >= 10mIU/mL (n = 105,116,120,112,156)100.0 (96.5 to 100.0)99.1 (95.3 to 100.0)99.2 (95.4 to 100.0)99.1 (95.1 to 100.0)98.7 (95.4 to 99.8)
PoliomyelitisType1 >=1:8titer (n=89,105,93,84,135)97.8 (92.1 to 99.7)98.1 (93.3 to 99.8)97.8 (92.4 to 99.7)100.0 (95.7 to 100.0)99.3 (95.9 to 100.0)
PoliomyelitisType2 >=1:8titer (n=89,105,93,84,135)95.5 (88.9 to 98.8)98.1 (93.3 to 99.8)95.7 (89.4 to 98.8)96.4 (89.9 to 99.3)95.6 (90.6 to 98.4)
PoliomyelitisType3 >=1:8titer (n=89,105,93,84,135)100.0 (95.9 to 100.0)100.0 (96.5 to 100.0)98.9 (94.2 to 100.0)98.8 (93.5 to 100.0)99.3 (95.9 to 100.0)
SecondaryPercentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose

Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.8 EU/mL, FHA \>=46.5 EU/mL, PRN \>=43.5 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.

Time frame:
1 month after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Hib PRP >=0.15 mcg/mL (n= 126, 135, 141, 138, 202)100.0 (97.1 to 100.0)99.3 (95.9 to 100.0)100.0 (97.4 to 100.0)100.0 (97.4 to 100.0)100.0 (98.2 to 100.0)
Hib PRP >=1 mcg/mL (n = 126, 135, 141, 138, 202)95.2 (89.9 to 98.2)96.3 (91.6 to 98.8)95.7 (91.0 to 98.4)95.7 (90.8 to 98.4)95.0 (91.1 to 97.6)
Pertussis PT >=14.8 EU/mL (n= 123,137,141,136,199)97.6 (93.0 to 99.5)99.3 (96.0 to 100.0)98.6 (95.0 to 99.8)100.0 (97.3 to 100.0)95.5 (91.6 to 97.9)
Pertussis FHA >=46.5 EU/mL (n=123,137,141,136,199)91.1 (84.6 to 95.5)94.9 (89.8 to 97.9)93.6 (88.2 to 97.0)92.6 (86.9 to 96.4)95.5 (91.6 to 97.9)
Pertussis PRN >=43.5 EU/mL (n=123,137,141,136,199)91.9 (85.6 to 96.0)94.9 (89.8 to 97.9)94.3 (89.1 to 97.5)94.1 (88.7 to 97.4)95.5 (91.6 to 97.9)
Tetanus >=0.1 IU/mL (n = 123,137,141,136,199)100.0 (97.0 to 100.0)100.0 (97.3 to 100.0)100.0 (97.4 to 100.0)100.0 (97.3 to 100.0)100.0 (98.2 to 100.0)
Diphtheria >=0.1 IU/mL (n = 123,137,141,136,199)100.0 (97.0 to 100.0)100.0 (97.3 to 100.0)100.0 (97.4 to 100.0)100.0 (97.3 to 100.0)100.0 (98.2 to 100.0)
HBV >= 10 mIU/mL (n = 119,131,133,133,191)100.0 (96.9 to 100.0)98.5 (94.6 to 99.8)100.0 (97.3 to 100.0)100.0 (97.3 to 100.0)99.5 (97.1 to 100.0)
Poliomyelitis 1 >=1:8titer (n=123,133,141,136,201)99.2 (95.6 to 100.0)100.0 (97.3 to 100.0)100.0 (97.4 to 100.0)100.0 (97.3 to 100.0)99.5 (97.3 to 100.0)
Poliomyelitis 2 >=1:8titer (n=123,133,141,136,201)100.0 (97.0 to 100.0)100.0 (97.3 to 100.0)100.0 (97.4 to 100.0)100.0 (97.3 to 100.0)100.0 (98.2 to 100.0)
Poliomyelitis 3 >=1:8titer (n=123,133,141,136,201)100.0 (97.0 to 100.0)100.0 (97.3 to 100.0)100.0 (97.4 to 100.0)100.0 (97.3 to 100.0)100.0 (98.2 to 100.0)
SecondaryPercentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1

Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree Celsius (degree C), greater than (\>) 39 but \<=40 degree C and \>40 degree C.

Time frame:
Within 4 days after infant series Dose 1
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Fever >=38, <=39 degree C (n= 149,157,147,155,187)32.945.218.434.241.7
Fever >39, <=40 degree C (n = 138,145,137,146,170)1.41.40.70.71.2
Fever >40 degree C (n = 138,145,137,146,170)0.00.00.00.00.0
SecondaryPercentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.

Time frame:
Within 4 days after infant series Dose 2
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Fever >=38, <=39 degree C (n= 141,152,140,159,181)26.242.821.444.039.8
Fever >39, <=40 degree C (n = 133,140,134,145,164)1.50.71.51.43.7
Fever >40 degree C (n = 131,140,133,144,164)0.00.00.00.00.0
SecondaryPercentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C. Report of fever \>40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error.

Time frame:
Within 4 days after infant series Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Fever >=38, <=39 degree C (n= 136,146,135,141,175)22.130.817.033.329.7
Fever >39, <=40 degree C (n = 129,137,125,136,167)1.62.90.81.51.8
Fever >40 degree C (n = 128,136,126,135,166)0.00.00.80.00.0
SecondaryPercentage of Participants Reporting Fever Within 4 Days: Toddler Dose

Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.

Time frame:
Within 4 days after toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Fever Within 4 Days: Toddler Dose
percentage of participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Fever >=38, <=39 degree C (n= 133,140,134,144,162)31.637.137.350.030.2
Fever >39, <=40 degree C (n = 128,127,118,123,150)5.57.14.25.72.0
Fever >40 degree C (n = 123,125,117,122,150)0.00.00.00.00.0
SecondaryNumber of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).

Time frame:
Baseline up to 1 Month (28 to 42 days) after infant series
Reported as:
Number · participants
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series
participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Non-SAEs5771677280
SAEs7311810
SecondaryNumber of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment).

Time frame:
1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose
Reported as:
Number · participants
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series
participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Non-SAEs36348
SAEs61410119
SecondaryNumber of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).

Time frame:
Toddler dose up to 1 Month (28 to 42 days) after toddler dose
Reported as:
Number · participants
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose
participants13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX Hexa
Non-SAEs4757527650
SAEs32111

Adverse events

Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary: fever (up to 4 days after each vaccine dose).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series—7/173 (4%)57/173 (32.9%)
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series—3/176 (1.7%)71/176 (40.3%)
13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series—11/172 (6.4%)67/172 (39%)
13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series—8/177 (4.5%)72/177 (40.7%)
13vPnC + INFANRIX Hexa - Infant Series—10/210 (4.8%)80/210 (38.1%)
13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser—6/170 (3.5%)3/170 (1.8%)
13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser—14/174 (8%)6/174 (3.4%)
13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser—10/172 (5.8%)3/172 (1.7%)
13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser—11/176 (6.3%)4/176 (2.3%)
13vPnC + INFANRIX Hexa - After Infant Series—9/210 (4.3%)8/210 (3.8%)
13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose—3/169 (1.8%)47/169 (27.8%)
13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose—2/173 (1.2%)57/173 (32.9%)
13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose—1/170 (0.6%)52/170 (30.6%)
13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose—1/175 (0.6%)76/175 (43.4%)
13vPnC + INFANRIX Hexa - Toddler Dose—1/209 (0.5%)50/209 (23.9%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
Event13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series13vPnC + INFANRIX Hexa - Infant Series13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser13vPnC + INFANRIX Hexa - After Infant Series13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose13vPnC + INFANRIX Hexa - Toddler Dose
GastroenteritisInfections and infestations0/1730/1760/1721/1771/2102/1704/1740/1721/1760/2100/1690/1731/1700/1750/209
PneumoniaInfections and infestations2/1730/1763/1722/1772/2101/1701/1742/1722/1761/2100/1690/1730/1700/1750/209
Gastroenteritis rotavirusInfections and infestations0/1730/1760/1720/1770/2100/1703/1741/1720/1760/2100/1690/1730/1700/1750/209
DiarrhoeaGastrointestinal disorders0/1731/1760/1720/1771/2100/1701/1741/1722/1763/2100/1690/1730/1700/1750/209
Head injuryInjury, poisoning and procedural complications0/1730/1760/1720/1771/2100/1700/1740/1720/1760/2102/1690/1730/1700/1750/209
BronchopneumoniaInfections and infestations2/1730/1760/1720/1771/2100/1700/1740/1720/1760/2100/1690/1730/1700/1750/209
Upper respiratory tract infectionInfections and infestations0/1730/1761/1720/1770/2100/1702/1740/1721/1760/2100/1691/1730/1700/1750/209
BronchitisInfections and infestations0/1730/1761/1722/1770/2100/1701/1740/1722/1760/2100/1690/1730/1700/1750/209
Urinary tract infectionInfections and infestations1/1732/1761/1722/1770/2100/1700/1741/1722/1760/2100/1690/1730/1700/1750/209
Viral infectionInfections and infestations0/1730/1760/1720/1770/2100/1700/1740/1720/1760/2101/1690/1730/1700/1750/209
Most frequent other events
Showing 10 of 107
Most frequent other events
Event13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series13vPnC + INFANRIX Hexa - Infant Series13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser13vPnC + INFANRIX Hexa - After Infant Series13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose13vPnC + INFANRIX Hexa - Toddler Dose
Fever >=38, <=39 degree CGeneral disorders49/14971/15727/14753/15578/187—————42/13352/14050/13472/14449/162
Fever >=38, <=39 degree CGeneral disorders37/14165/15230/14070/15972/181——————————
Fever >=38, <=39 degree CGeneral disorders30/13645/14623/13547/14152/175——————————
Upper respiratory tract infectionInfections and infestations15/17312/17614/17217/17712/2100/1700/1740/1720/1760/2107/1697/1733/1704/1757/209
NasopharyngitisInfections and infestations11/1736/17610/1728/17718/2100/1700/1740/1720/1761/2101/1692/1734/1702/1751/209
Fever >39, <=40 degree CGeneral disorders2/1382/1451/1371/1462/170—————7/1289/1275/1187/1233/150
BronchitisInfections and infestations9/1738/17611/1729/1775/2100/1700/1740/1720/1761/2102/1690/1733/1705/1752/209
RhinitisInfections and infestations3/1737/17611/17210/1779/2100/1700/1741/1720/1760/2102/1694/1735/1703/1755/209
ConjunctivitisEye disorders1/1733/1767/1725/1770/2100/1700/1740/1720/1760/2101/1690/1730/1700/1751/209
Respiratory tract infectionInfections and infestations4/1737/1764/1725/1773/2100/1700/1740/1720/1760/2100/1691/1730/1706/1752/209

Baseline characteristics

Age, Continuous
Age, Continuous(days)13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX HexaTotal
Mean65.1 ± 9.566.5 ± 10.165.6 ± 9.766.4 ± 10.365.6 ± 9.465.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC + INFANRIX Hexa + Paracetamol Twice Daily13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily13vPnC + INFANRIX HexaTotal
Female8789757998428
Male86879798112480
08

Study locations

14 sites
  • Gabinet Lekarski
    Debica, 39-200, Poland
  • Hanna Czajka Indywidualna Praktyka Lekarska
    Krakow, 31-302, Poland
  • NZOZ "Praktimed" sp. z o.o.
    Krakow, 31-422, Poland
  • NZOZ Salmed
    Leczna, 21-010, Poland
  • Specjalistyczna Praktyka Lekarska Gravita
    Lodz, 91-347, Poland
  • SP ZOZ Lubartow
    Lubartow, 21-100, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Eskulap
    Lublin, 20-044, Poland
  • NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak
    Oborniki Slaskie, 55-120, Poland
  • Specjalistyczny ZOZ nad Matka i Dzieckiem, Oddzial Obserwacyjno Zakazny A, Szpital Dzieciecy
    Poznan, 61-734, Poland
  • NZLA Michalkowice Jarosz i Partnerzy
    Siemianowice Slaskie, 41-103, Poland
  • NZOZ Nasz Lekarz
    Torun, 87-100, Poland
  • Szpital im. Sw. Jadwigi Slaskiej, Oddzia Pediatryczny
    Trzebnica, 55-100, Poland
  • DEN-MED Gabinet Lekarsko-Stomatologiczny Joanna i Jacek Witwiccy
    Warszawa, 02-127, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu
    Wroclaw, 50-345, Poland
09

References and documents

Publications

  • Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopinska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3. PubMed 28262330 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2011
First posted
Jul 12, 2011
Start
Aug 2011
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Feb 26, 2014
Last update
Feb 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01392378
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Aug 2011
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Feb 26, 2014
Last update
Feb 26, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion